Canada: Health Canada

The national authority

Health Canada is the federal department responsible for regulating drugs, medical devices, and other health products across Canada. Within it, the Health Products and Food Branch oversees the system, with specialized directorates handling pharmaceuticals and medical devices.

Because Canada is a federation, some aspects of health delivery sit with the provinces, but the authorization of drugs and devices for sale is federal and applies nationwide, including in bilingual labeling requirements reflecting the country's two official languages.

How products enter the market

Prescription and over-the-counter medicines are authorized through drug submissions: a New Drug Submission for new products and an Abbreviated New Drug Submission for generics, which demonstrates equivalence to an approved reference product. Authorized medicines receive a Drug Identification Number, the eight-digit identifier that appears on every authorized drug label and anchors Canada's drug product databases.

Medical devices follow a four-class risk model. Low-risk Class I devices do not need individual licences but require the seller to hold an establishment licence. Classes II, III, and IV require a Medical Device Licence with progressively deeper evidence review, and higher-risk devices must show clinical evidence of safety and effectiveness.

Access and post-market oversight

For patients with serious or life-threatening conditions who cannot use authorized products, the Special Access Programme allows practitioners to request access to unauthorized drugs on a case-by-case basis.

After authorization, Health Canada runs post-market surveillance: manufacturers must report adverse reactions, and the department can require label changes, communicate safety warnings, or suspend or cancel an authorization when evidence warrants.

Priority review and conditional authorization (Notice of Compliance with conditions) exist for drugs addressing serious conditions where promising early evidence justifies faster access.

Using this profile

Administrators and researchers should treat the Drug Identification Number and the licensed-device lists as the primary records of product status, and note that many authoritative records are published in both English and French.

For cross-country comparison: Canada's device classification aligns broadly with the European model, and its drug review timelines and reliance practices are shaped by close alignment with, but independence from, the United States system. The authority portal listed in this profile's internal reference record is the primary source for current rules and databases.